Two- versus five-fraction stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: feasibility of randomization, clinical tolerance and early oncologic control

Clinical and Translational Radiation Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles